ArticleFrontiers in microbiology2021
Article in Frontiers in microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Purification, Characterization, and In Vitro Safety Assessment of the Antimicrobial Peptide SAM-KB40 from Bacillus licheniformis SAM-D318.Applied biochemistry and biotechnology · 2026Article
- Peptidomic Characterization of < 3 kDa Peptides from Milk Fermented by Lactic Acid Bacteria: Sequence-Based Antimicrobial Prediction and In Vitro Immuno-Oncological Evaluation.Probiotics and antimicrobial proteins · 2026Article
- Deep learning-driven integrated pipeline for de novo design and synthesis of antimicrobial peptides.npj drug discovery · 2026Article
- One-Step Design of Potent and Nonhemolytic Antimicrobial Peptides by Using a Database-Guided, Nonmachine Learning Approach.ACS infectious diseases · 2026Article
- Artificial Intelligence as a Catalyst for Antimicrobial Discovery: From Predictive Models to De Novo Design.Microorganisms · 2026Review
- APD6: the antimicrobial peptide database is expanded to promote research and development by deploying an unprecedented information pipeline.Nucleic acids research · 2026Article
- Reverse Vaccinology and Immunoinformatics Strategy to Screen Oncogenic Proteins and Development of a Multiepitope Peptide Vaccine Targeting Protein Kinases against Oral Cancer: An in-silico Study.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- Innovative Strategies and Methodologies in Antimicrobial Peptide Design.Journal of functional biomaterials · 2024Review
- Tackling the Antimicrobial Resistance "Pandemic" with Machine Learning Tools: A Summary of Available Evidence.Microorganisms · 2024Review
- Exploratory data analysis of physicochemical parameters of natural antimicrobial and anticancer peptides: Unraveling the patterns and trends for the rational design of novel peptides.BioImpacts : BI · 2024Article
- GATR-3, a Peptide That Eradicates Preformed Biofilms of Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2023Article
- Peptides as Therapeutic Agents: Challenges and Opportunities in the Green Transition Era.Molecules (Basel, Switzerland) · 2023Review
- The antimicrobial peptide database is 20 years old: Recent developments and future directions.Protein science : a publication of the Protein Society · 2023Article
- Article
- Computationally Designed AMPs with Antibacterial and Antibiofilm Activity against MDRAntibiotics (Basel, Switzerland) · 2023Article
- Antimicrobial Peptides Demonstrate Activity against Resistant Bacterial Pathogens.Infectious disease reports · 2023Review
- Isolation and Optimization of a Broad-Spectrum Synthetic Antimicrobial Peptide, Ap920-WI, fromInternational journal of molecular sciences · 2023Article
- Antimicrobial Peptides Therapy: An Emerging Alternative for Treating Drug-Resistant Bacteria.The Yale journal of biology and medicine · 2022Review
- Article
- Pathogen-Specific Bactericidal Method Mediated by Conjugative Delivery of CRISPR-Cas13a Targeting Bacterial Endogenous Transcripts.Microbiology spectrum · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Antimicrobial peptides (AMPs) are ubiquitous amongst living organisms and are part of the innate immune system with the ability to kill pathogens directly or indirectly by modulating the immune system. AMPs have potential as a novel therapeutic against bacteria due to their quick-acting mechanism of action that prevents bacteria from developing resistance. Additionally, there is a dire need for therapeutics with activity specifically against Gram-negative bacterial infections that are intrinsically difficult to treat, with or without acquired drug resistance. Development of new antibiotics has slowed in recent years and novel therapeutics (like AMPs) with a focus against Gram-negative bacteria are needed. We designed eight novel AMPs, termed PHNX peptides, using
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.